Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryuji Koike

Showing results (31-40 of 109) with videos related to

Pageof 11
Sort By:
European Journal of Pharmacology|March 27, 2025
Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse modelsSeiya Oba, Tadashi Hosoya, Daisuke Kawata, et al.
International Journal of Rheumatic Diseases|April 19, 2018
No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance databaseRyoko Sakai, Shoko Kasai, Fumio Hirano, et al.
Arthritis Research & Therapy|March 14, 2020
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritisWaka Yokoyama-Kokuryo, Hayato Yamazaki, Tsutomu Takeuchi, et al.
The Analyst|October 7, 2022
Rapid and sensitive SARS-CoV-2 detection using a homogeneous fluorescent immunosensor Quenchbody with crowding agentsBo Zhu, Nobuyuki Nosaka, Shuji Kanamaru, et al.
Gut Pathogens|November 9, 2019
Hypervirulent clade 2, ribotype 019/sequence type 67 <i>Clostridioides difficile</i> strain from JapanRyoichi Saito, Yukino Usui, Alafate Ayibieke, et al.
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|April 4, 2006
[Case of dermatomyositis complicated with massive pleural effusion that preceded the myopathy]Hideyuki Iwai, Ryuji Koike, Jun Ogawa, et al.
Blood Neoplasia|June 23, 2025
JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 studyYu Uemura, Masahide Yamamoto, Masataka Ishimura, et al.
International Journal of Molecular Sciences|May 14, 2025
Unraveling the COVID-19 Severity Hubs and Interplays in Inflammatory-Related RNA-Protein NetworksHeewon Park, Qingbo S Wang, Takanori Hasegawa, et al.
Diabetes, Obesity & Metabolism|September 3, 2022
Clinical significance of prediabetes, undiagnosed diabetes and diagnosed diabetes on critical outcomes in COVID-19: Integrative analysis from the Japan COVID-19 task forceTakahiro Fukushima, Shotaro Chubachi, Ho Namkoong, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2014
First report of KPC-2 Carbapenemase-producing Klebsiella pneumoniae in JapanRyoichi Saito, Rieko Takahashi, Etsuko Sawabe, et al.
Pageof 11

Showing results (31-40 of 109) with videos related to

Sort By:
Pageof 11
European Journal of Pharmacology|March 27, 2025
Iguratimod, a promising therapeutic agent for COVID-19 that attenuates excessive inflammation in mouse modelsSeiya Oba, Tadashi Hosoya, Daisuke Kawata, et al.
International Journal of Rheumatic Diseases|April 19, 2018
No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance databaseRyoko Sakai, Shoko Kasai, Fumio Hirano, et al.
Arthritis Research & Therapy|March 14, 2020
Identification of molecules associated with response to abatacept in patients with rheumatoid arthritisWaka Yokoyama-Kokuryo, Hayato Yamazaki, Tsutomu Takeuchi, et al.
The Analyst|October 7, 2022
Rapid and sensitive SARS-CoV-2 detection using a homogeneous fluorescent immunosensor Quenchbody with crowding agentsBo Zhu, Nobuyuki Nosaka, Shuji Kanamaru, et al.
Gut Pathogens|November 9, 2019
Hypervirulent clade 2, ribotype 019/sequence type 67 <i>Clostridioides difficile</i> strain from JapanRyoichi Saito, Yukino Usui, Alafate Ayibieke, et al.
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|April 4, 2006
[Case of dermatomyositis complicated with massive pleural effusion that preceded the myopathy]Hideyuki Iwai, Ryuji Koike, Jun Ogawa, et al.
Blood Neoplasia|June 23, 2025
JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 studyYu Uemura, Masahide Yamamoto, Masataka Ishimura, et al.
International Journal of Molecular Sciences|May 14, 2025
Unraveling the COVID-19 Severity Hubs and Interplays in Inflammatory-Related RNA-Protein NetworksHeewon Park, Qingbo S Wang, Takanori Hasegawa, et al.
Diabetes, Obesity & Metabolism|September 3, 2022
Clinical significance of prediabetes, undiagnosed diabetes and diagnosed diabetes on critical outcomes in COVID-19: Integrative analysis from the Japan COVID-19 task forceTakahiro Fukushima, Shotaro Chubachi, Ho Namkoong, et al.
Antimicrobial Agents and Chemotherapy|February 26, 2014
First report of KPC-2 Carbapenemase-producing Klebsiella pneumoniae in JapanRyoichi Saito, Rieko Takahashi, Etsuko Sawabe, et al.
Pageof 11